March 5, 2020 / 12:19 PM / a month ago

BRIEF-Idera Pharmaceuticals Completes Enrollment In Illuminate-301, Its Registrational Trial Of Tilsotolimod In Combination With Ipilimumab In Patients With Anti-Pd-1 Refractory Advanced Melanoma

March 5 (Reuters) - Idera Pharmaceuticals Inc:

* IDERA PHARMACEUTICALS COMPLETES ENROLLMENT IN ILLUMINATE-301, ITS REGISTRATIONAL TRIAL OF TILSOTOLIMOD IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ANTI-PD-1 REFRACTORY ADVANCED MELANOMA

* IDERA PHARMA- EXPECTS TOP-LINE OVERALL RESPONSE RATE AND OTHER PRELIMINARY DATA FROM ILLUMINATE-301 IN Q1 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below